GEN Exclusives

More »

GEN News Highlights

More »
Oct 2, 2012

Lonza to Manufacture Heart Failure Enzyme Replacement Therapy

  • Lonza is to carry out GMP manufacture of Celladon’s Phase IIb-stage targeted enzyme replacement therapy candidate Mydicar® (AAV1/SERCA2a) for clinical trials, and potentially for commercial supply. The viral vector-based treatment is designed to restore levels of the SERCA2a, a regulator of calcium cycling in the heart, and cardiac contractility. Lonza says it will manufacture Mydicar initially at the 1,000 liter scale and potentially up to 2,000 liters, at its recently completed and validated suite.

    “This is an important milestone in the Mydicar® development program,” comments Krisztina Zsebo, Ph.D., Celladon president and CEO. “Lonza’s large-scale viral manufacturing expertise will greatly complement and support our future development and commercialization efforts for Mydicar."

    Levels of SERCA2a decline in all forms of late-stage heart failure, resulting in deficient heart function. Mydicar has been developed as a recombinant AAV-based vector carrying the SERCA2a-gene, which is administered in a single dose directly to the heart during routine outpatient cardiac catheterization procedure. The product is undergoing Phase II trials in patients with advanced heart failure. Earlier this year Celladon raised $53 million in a venture financing round to support continued clinical development of the product. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »